After speaking with management, Jefferies analyst Brian Abrahams says the partial clinical hold placed by the FDA on Karyopharm's lead drug selinexor is "purely an administrative error." The hold does not at all reflect any new safety issue and should not materially affect trial conduct and enrollment timelines, Abrahams tells investors in a research note titled "Headline Looks Far Worse Than It Is- Partial Hold Just An Administrative Blunder." The analyst recommends buying Karyopharm on weakness. He keeps a Buy rating on the shares with a $14 price target.